Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, Agnes S. M. Yong, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, David M Ross, Timothy P. Hughes, MD

Blood (2018) 132 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2018-99-111083

Published: 2018

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Emily Blyth, Barbara Withers, Leighton Edward Clancy, PhD, Agnes S. M. Yong, MDPhD, Christopher Fraser, MD, Jane Burgess, Renee Simms, Gloria Castellano Gonzalez, PhD, David Kliman, MBBS, Ming-Celine Dubosq, MD, David Bishop, Gaurav Sutrave, MBBS,, Chun Kei Kris Ma, PhDMBBS, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1919.

https://doi.org/10.1182/blood.V130.Suppl_1.1919.1919

Published: 2017

Journal Articles

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Amy Hughes, PhD, Jade Clarson, Deborah L White, PhD FFSc (RCPA), David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S. M. Yong, MDPhD

Blood (2017) 130 (Supplement 1): 1581.

https://doi.org/10.1182/blood.V130.Suppl_1.1581.1581

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

NARROW

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Email alerts

ASH Publications

American Society of Hematology

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only